CCP
XPH icon

Corient Capital Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Corient Capital Partners’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-26,183
Closed -$959K – 383
2018
Q4 		$959K Buy
+26,183
New +$1.12M 0.17% 150

Other funds holding XPH

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Corient Capital Partners's XPH Position: Q1 2019 in Review

Corient Capital Partners sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2019, closing a stake of 26,183 shares — an estimated $959K sold.

Corient Capital Partners first reported a position in XPH in Q4 2018 and held it in 1 quarter. The position peaked at $959K in Q4 2018. 80 funds tracked by Wall St. Rank hold XPH as of Q1 2019.

  • Corient Capital Partners reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2019 after selling out during the quarter.
  • Corient Capital Partners sold 26,183 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2019, an estimated $959K.
  • Corient Capital Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2018 and held it in 1 quarter.
  • Corient Capital Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $959K in Q4 2018.
  • 80 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2019.

Based on Corient Capital Partners's 13F filing for Q1 2019, filed 10 May 2019.